FKBP5 and prostate cancer: In contrast, another study focused on prostate cancer revealed a decrease in the mRNA levels of AR and AR-V7 (constitutively active variants), along with their targets kallikrein-related peptidase 3 (KLK3), FK506-binding protein 5 (FKBP5), and NKX3, following MLN4924 treatment and NAE knockdown.